TickerTalks
Browse all tickers →
TickerTalks›$PRME
PRPRME

Prime Medicine, Inc.

$PRME·$556M·Biotechnology·Healthcare
$3.09-2.5%YTD-14.9%1Y-15.1%
Mentions · last 7 days
2026-08-08: 8 posts2026-08-09: 15 posts2026-08-10: 17 posts2026-08-11: 10 posts2026-08-12: 25 posts2026-08-13: 12 posts2026-08-14: 20 posts107+32%
Price updated 23h ago·X counts updated 21h ago
PRPRME
$PRMEPrime Medicine, Inc.
$3.09-2.52%107 posts+32%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $PRME, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-15

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Prime-editing platform with unusually clean recent catalyst string — RMAT designation, patent win over Beam, and the first in-vivo IND clearance in the modality.

Prime Medicine is in the phase every gene-editing platform company hopes to reach: the underlying science is producing regulatory milestones, and the market is starting to notice.

  • Q1 revenue $856K on a $556M market cap — this is not a fundamentals story, it's a platform-milestone story.
  • FDA RMAT designation for the lead program (June) is a substantive de-risking signal.
  • Binding arbitration with Beam Therapeutics resolved in Prime's favor (July) — removes a key IP overhang that had been suppressing the multiple.
  • First-ever in-vivo prime-editing IND cleared by FDA (July) — for PM577a in H1069Q-mutated Wilson Disease.
  • August 10-Q established going-concern position without immediate dilution — analyst consensus loss of -$0.99 for FY26 requires cash runway.
  • USPTO published Prime's cystic-fibrosis prime-editing patent application; speculation that Prime is the undisclosed 'leading Gene Editing company' in the ReCode CFTR collaboration.
  • Beta 2.31 — moves are violent in either direction on data prints.

The risk is binary: any clinical readout can gap the stock 30%+ in either direction, and the cash runway to next raise is the ceiling on how many catalysts get funded.

Agrees with X sentimentThe X bull take on the catalyst string (RMAT, Beam arbitration, in-vivo IND, going-concern removal) is accurate and materially derisks the platform. What the chatter is underweighting is that gene editing has repeatedly shown clean preclinical/regulatory milestones followed by disappointing clinical translation — the first in-human data are the real test.

What to watch: Cash runway commentary at the Q3 print (November 6), any clinical trial initiation timelines for PM577a, and any confirmation of the ReCode CFTR collaboration attribution. New IND clearances would extend the catalyst string.

On the calendar: Q3 earnings Nov 6

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment23 posts analyzed · as of 2026-08-14

Prime Medicine chatter is emphatically bullish. Anchor catalysts: FDA granted RMAT designation to lead program in June, binding arbitration with Beam Therapeutics resolved in PRME's favor in July, first in vivo therapy cleared US IND, Aug 6 10-Q established a confirmed going-concern position and no share dilution. USPTO published PRME's cystic-fibrosis prime-editing application. A 72-page institutional research report titled 'Prime Medicine: Platform Validation at the Inflection' generated buzz. Speculation that PRME is the undisclosed 'leading Gene Editing company' in the ReCode CFTR collaboration. No bear voice.

Read the AI verdict + X sentiment for $PRME

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops prime editing gene therapies enabling precise genomic insertions and corrections for inherited diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PRME.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $PRME

Neutral — Develops prime editing gene therapies enabling precise genomic insertions and corrections for inherited diseases; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-77.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-51.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-28.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
137.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-189%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-10.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.24$-0.26+6.7%
Q1 2026May 7, 2026$-0.28$-0.24-16.7%
Q4 2025Mar 3, 2026$-0.22$-0.25+12.0%
Q3 2025Nov 7, 2025$-0.32$-0.28-14.3%
Next earningsFri, Nov 6·consensus EPS $-0.23

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$856K-41.1%-117%-5918%$-0.28$-42.9M
Q4 FY25$838K-61.6%100%-5800%$-0.26$-37.5M
Q3 FY25$1.2M+486.1%-3491%-4406%$-0.32$-35.3M
Q2 FY25$1.1M—-67.2%-4787%$-0.41$-43.0M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$12.2M$813K – $47.3M-$1.00-$1.19 – -$0.9110
FY27$21.0M$3.6M – $52.5M-$0.88-$1.11 – -$0.718
FY28$28.4M$3.3M – $114.8M-$0.80-$1.11 – -$0.5610
FY29$15.7M$1.8M – $63.6M-$0.91-$4.52 – $0.135
FY30$50.9M$6.0M – $206.2M-$0.82-$4.04 – $0.125

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.10%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-5.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-13.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 59.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.315-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 11 other (11 awards) in window

See when $PRME insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 88-K — Item 5.07: Shareholder vote
AI summary

Prime Medicine, Inc. held its 2026 Annual Meeting on June 5, 2026, with 140.4 million of 180.6 million eligible shares represented (77.7%). Stockholders voted to elect Michael Kelly and David Schenkein, M.D. as Class I directors for terms through 2029, and to ratify PricewaterhouseCoopers LLP as auditor for fiscal 2026. Routine governance — no contested proposals.

3New insider — initial holdingsApr 173
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for PRME on 2026-04-17, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KOfficer or director changeApr 168-K — Item 5.02: Officer or director change
AI summary

PRME disclosed a personnel change (8-K Item 5.02, dated 2026-04-16). An executive departure and a new appointment are both reported. Svetlana Makhni as the Chief Financial. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KPress release / Reg FDMar 38-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 14 other (2 10-Qs · 2 earnings 8-Ks · 2 proxys · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimateszacks.com·9d agoPrime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Releasezacks.com·16d agoPrime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Diseaseglobenewswire.com·23d agoPrime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc.defenseworld.net·26d agoPrime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investableseekingalpha.com·37d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPRAI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$TENX$AURA$SION$IBRX
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport